BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 11262262)

  • 1. [Evolution of a case of tyrosinemia type I treated with NTBC].
    Ros Viladoms J; Vilaseca Buscà MA; Lambruschini Ferri N; Mas Comas A; González Pascual E; Holme E
    An Esp Pediatr; 2001 Mar; 54(3):305-9. PubMed ID: 11262262
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tyrosinemia type I treated by NTBC: how does AFP predict liver cancer?
    Koelink CJ; van Hasselt P; van der Ploeg A; van den Heuvel-Eibrink MM; Wijburg FA; Bijleveld CM; van Spronsen FJ
    Mol Genet Metab; 2006 Dec; 89(4):310-5. PubMed ID: 17008115
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pregnancy in an NTBC-treated patient with hereditary tyrosinemia type I.
    Kassel R; Sprietsma L; Rudnick DA
    J Pediatr Gastroenterol Nutr; 2015 Jan; 60(1):e5-7. PubMed ID: 23838819
    [No Abstract]   [Full Text] [Related]  

  • 4. Kidneys of mice with hereditary tyrosinemia type I are extremely sensitive to cytotoxicity.
    Jacobs SM; van Beurden DH; Klomp LW; Berger R; van den Berg IE
    Pediatr Res; 2006 Mar; 59(3):365-70. PubMed ID: 16492973
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hepatocellular carcinoma in hereditary tyrosinemia type I despite 2-(2 nitro-4-3 trifluoro- methylbenzoyl)-1, 3-cyclohexanedione treatment.
    van Spronsen FJ; Bijleveld CM; van Maldegem BT; Wijburg FA
    J Pediatr Gastroenterol Nutr; 2005 Jan; 40(1):90-3. PubMed ID: 15625434
    [No Abstract]   [Full Text] [Related]  

  • 6. [Clinical follow up of Chilean patients with tyrosinemia type 1 treated with 2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-ciclohexanedione (NTBC)].
    Raimann E; Cornejo V; Arias C; Cabello JF; Castro G; Fernández E; de la Parra A
    Rev Med Chil; 2012 Feb; 140(2):169-75. PubMed ID: 22739945
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Late Development of Hepatocellular Carcinoma in Tyrosinemia Type 1 Despite Nitisinone (NTBC) Treatment.
    Almuqbil M; Knoll J; Chinsky JM
    J Pediatr Gastroenterol Nutr; 2020 Aug; 71(2):e73-e75. PubMed ID: 32141999
    [No Abstract]   [Full Text] [Related]  

  • 8. Experience of nitisinone for the pharmacological treatment of hereditary tyrosinaemia type 1.
    Santra S; Baumann U
    Expert Opin Pharmacother; 2008 May; 9(7):1229-36. PubMed ID: 18422479
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tyrosinemia I, a model for human diseases mediated by 2-oxoacid-utilizing dioxygenases: hepatotoxin suppression by NTBC does not normalize hepatic collagen metabolism.
    Hanauske-Abel HM; Popowicz A; Remotti H; Newfield RS; Levy J
    J Pediatr Gastroenterol Nutr; 2002 Jul; 35(1):73-8. PubMed ID: 12142814
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In brief: Nitisinone (Orfadin) for hereditary tyrosinemia.
    Med Lett Drugs Ther; 2016 Oct; 58(1505):e132. PubMed ID: 27701365
    [No Abstract]   [Full Text] [Related]  

  • 11. Confocal microscopy of corneal crystals in a patient with hereditary tyrosinemia type I, treated with NTBC.
    Schauwvlieghe PP; Jaeken J; Kestelyn P; Claerhout I
    Cornea; 2013 Jan; 32(1):91-4. PubMed ID: 22495034
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tyrosinemia type 1: metastatic hepatoblastoma with a favorable outcome.
    Nobili V; Jenkner A; Francalanci P; Castellano A; Holme E; Callea F; Dionisi-Vici C
    Pediatrics; 2010 Jul; 126(1):e235-8. PubMed ID: 20547648
    [TBL] [Abstract][Full Text] [Related]  

  • 13. LC-MS/MS method for simultaneous determination on a dried blood spot of multiple analytes relevant for treatment monitoring in patients with tyrosinemia type I.
    la Marca G; Malvagia S; Materazzi S; Della Bona ML; Boenzi S; Martinelli D; Dionisi-Vici C
    Anal Chem; 2012 Jan; 84(2):1184-8. PubMed ID: 22148291
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The fate of tyrosinaemic Hungarian patients before the NTBC aera.
    László A; Rózsa M; Sallay E; Tiszlavicz L; Janovszky A; Várkonyi A; Karg E; Wittmann G; Túri S; Ugarte M
    Ideggyogy Sz; 2013 Nov; 66(11-12):415-9. PubMed ID: 24555242
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Liver Cancer in Tyrosinemia Type 1.
    van Ginkel WG; Pennings JP; van Spronsen FJ
    Adv Exp Med Biol; 2017; 959():101-109. PubMed ID: 28755188
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impaired cognitive functioning in patients with tyrosinemia type I receiving nitisinone.
    Bendadi F; de Koning TJ; Visser G; Prinsen HC; de Sain MG; Verhoeven-Duif N; Sinnema G; van Spronsen FJ; van Hasselt PM
    J Pediatr; 2014 Feb; 164(2):398-401. PubMed ID: 24238861
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tyrosinaemia type I and NTBC (2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione).
    Holme E; Lindstedt S
    J Inherit Metab Dis; 1998 Aug; 21(5):507-17. PubMed ID: 9728331
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reversibility of cirrhotic regenerative liver nodules upon NTBC treatment in a child with tyrosinaemia type I.
    Crone J; Möslinger D; Bodamer OA; Schima W; Huber WD; Holme E; Stöckler Ipsiroglu S
    Acta Paediatr; 2003 May; 92(5):625-8. PubMed ID: 12839296
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nontransplant treatment of tyrosinemia.
    Holme E; Lindstedt S
    Clin Liver Dis; 2000 Nov; 4(4):805-14. PubMed ID: 11232358
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Favorable outcome of treatment with NTBC of acute liver insufficiency disclosing hereditary tyrosinemia type I].
    Barkaoui E; Debray D; Habès D; Ogier H; Bernard O
    Arch Pediatr; 1999 May; 6(5):540-4. PubMed ID: 10370811
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.